AI-generated analysis. Always verify with the original filing.
Aurinia Pharmaceuticals Inc. appointed Kevin Tang as CEO and principal executive officer, Ryan Cole as COO, and Michael Hearne as CFO and principal financial officer, effective March 23, 2026, following the departure of prior executives including Peter Greenleaf on March 20, 2026. Craig Johnson was appointed Lead Independent Director effective March 21, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release dated March 23, 2026 104 Cover Page Interactive Data File (the cover
Kevin Tang
Effective: 2026-03-23
Ryan Cole
Effective: 2026-03-23
Michael Hearne
Effective: 2026-03-23
Peter Greenleaf
Effective: 2026-03-20
Matthew Donley
Effective: 2026-03-20
Gregory Keenan, M.D.
Effective: 2026-03-20
Joseph Miller
Effective: 2026-03-20
Craig Johnson
Effective: 2026-03-21